Newron Pharmaceuticals S.p.A. Stock
Stocks
NWRN
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
19:30:01 02/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 8.840 CHF | -1.78% |
|
+2.31% | -62.94% |
| 10-22 | Newron Pharmaceuticals S.p.A. Completes Enrollment In Pivotal Phase 3 ENIGMA-TRS 1 Study | CI |
| 10-22 | Newron Pharmaceuticals Completes Enrollment for Schizophrenia Drug Late-stage Trial | MT |
| Market Cap | 204M 229M 187M 170M 319M 21.64B 326M 2.24B 902M 11.42B 858M 840M 36.08B | P/E 2026 * |
-6.2x | P/E 2027 * | 16.5x |
|---|---|---|---|---|---|
| Enterprise Value | 218M 245M 200M 182M 342M 23.15B 348M 2.39B 965M 12.22B 918M 898M 38.59B | EV / Sales 2026 * |
26.2x | EV / Sales 2027 * | 3.84x |
| Free-Float |
87.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NWRN | Delayed | |
Xetra
| NP5 | Delayed | |
|
Tradegate
| NP5 | Real-time | |
|
CBOE
| 0QOI | Real-time | |
|
Boerse Muenchen
| NP5 | Real-time | |
|
Deutsche Boerse AG
| NP5 | Delayed | |
|
Börse Stuttgart
| NP5 | Delayed |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | -1.78% | ||
| 1 week | -2.86% | ||
| Current month | -1.78% | ||
| 1 month | +8.87% | ||
| 3 months | -23.79% | ||
| 6 months | -35.94% | ||
| Current year | -62.94% |
| 1 week | 8.68 |  | 9.4 |
| 1 month | 5.72 | | 9.4 |
| Current year | 5.72 | | 31.85 |
| 1 year | 5.72 | | 31.85 |
| 3 years | 4.09 | | 31.85 |
| 5 years | 1.01 | | 31.85 |
| 10 years | 0.9 | | 31.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/12/26 A | Buy | Chief Executive Officer | 2,000 | 0.0096% | ||
| 8/11/26 A | Buy | Chief Technology Officer | 582 | 0.0028% | ||
| 8/10/26 A | Buy | Chief Technology Officer | 1,418 | 0.0068% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.78% | -2.86% | -37.30% | +84.17% | 232M | |
| -2.37% | -4.19% | +39.49% | +63.21% | 63.77B | |
| -2.87% | +0.49% | +10.45% | +69.18% | 56.37B | |
| +0.62% | +2.11% | +20.22% | +102.56% | 54.62B | |
| -3.72% | -5.02% | +21.50% | +36.44% | 44.06B | |
| -2.23% | -1.75% | +16.84% | +100.16% | 42.11B | |
| -1.14% | +3.30% | +220.20% | +798.23% | 41B | |
| -5.47% | +24.76% | +98.34% | +87.34% | 34.92B | |
| +0.21% | -1.23% | +14.81% | +47.35% | 32.82B | |
| -2.71% | +18.76% | -40.48% | +343.16% | 24.7B | |
| Average | -2.11% | +7.37% | +36.41% | +173.18% | 39.46B | |
| Weighted average by Cap. | -2.07% | +5.64% | +45.13% | +165.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.32M 9.32M 7.64M 6.95M 13.02M 882M 13.28M 91.22M 36.77M 466M 34.98M 34.24M 1.47B | 57.9M 64.85M 53.13M 48.33M 90.61M 6.14B 92.41M 635M 256M 3.24B 243M 238M 10.23B |
| Net income | -32.8M -36.74M -30.1M -27.38M -51.33M -3.48B -52.36M -360M -145M -1.84B -138M -135M -5.8B | 9.39M 10.52M 8.62M 7.84M 14.7M 996M 14.99M 103M 41.49M 526M 39.48M 38.64M 1.66B |
| Net Debt | 14.21M 15.92M 13.04M 11.86M 22.24M 1.51B 22.68M 156M 62.78M 795M 59.74M 58.46M 2.51B | 18.13M 20.31M 16.64M 15.14M 28.38M 1.92B 28.94M 199M 80.11M 1.01B 76.22M 74.6M 3.21B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/11/26 | CHF 8.840 | -1.78% | 21,247 |
| 30/10/26 | CHF 9.000 | -1.42% | 40,268 |
| 29/10/26 | CHF 9.130 | +3.28% | 62,206 |
| 28/10/26 | CHF 8.840 | -1.56% | 53,306 |
| 27/10/26 | CHF 8.980 | -1.32% | 50,546 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
Select your edition
All financial news and data tailored to specific country editions
